

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **August 2019**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IMV Inc.**

Date: August 8, 2019

By: /s/ Pierre Labbé

Name: Pierre Labbé

Title: Chief Financial Officer

---

Form 6-K Exhibit Index

Exhibit Number	Document Description
99.1	<a href="#">Interim Financial Statements for the period ended June 30, 2019</a>
99.2	<a href="#">Management Discussion and Analysis for the period ended June 30, 2019</a>
99.3	<a href="#">CEO certification</a>
99.4	<a href="#">CFO certification</a>

---



Unaudited Interim Condensed Consolidated  
Financial Statements  
**June 30, 2019**

---

August 8 , 2019

**Management's Responsibility for Financial Reporting**

The accompanying unaudited interim condensed consolidated financial statements of **IMV Inc. (the "Corporation")** are the responsibility of management and have been approved by the Board of Directors. The consolidated financial statements have been prepared by management in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. The consolidated financial statements include some amounts and assumptions based on management's best estimates which have been derived with careful judgment.

In fulfilling its responsibilities, management has developed and maintains a system of internal accounting controls. These controls are designed to ensure that the financial records are reliable for preparation of the consolidated financial statements. The Audit Committee of the Board of Directors reviewed and approved the Corporation's consolidated financial statements, and recommended their approval by the Board of Directors.

(signed) "*Frederic Ors*"  
Chief Executive Officer

(signed) "*Pierre Labbé*"  
Chief Financial Officer

---

**IMV Inc.**

Unaudited Interim Condensed Consolidated Statements of Financial Position

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
	<b>\$</b>	<b>\$</b>
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	26,904	14,895
Amounts receivable	1,285	1,337
Prepaid expenses	4,343	2,699
Investment tax credits receivable	1,750	1,111
	<u>34,282</u>	<u>20,042</u>
<b>Property and equipment</b>	<u>3,063</u>	<u>2,883</u>
	<u>37,345</u>	<u>22,925</u>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Accounts payable and accrued liabilities	5,733	7,575
Amounts due to directors	63	49
Current portion of long-term debt (note 5)	86	81
Current portion of lease obligation	95	90
	<u>5,977</u>	<u>7,795</u>
<b>Lease obligation</b>	1,259	1,308
<b>Deferred share units (note 4)</b>	1,046	1,436
<b>Long-term debt (note 5)</b>	<u>7,972</u>	<u>8,069</u>
	<u>16,254</u>	<u>18,608</u>
<b>Equity</b>	<u>21,091</u>	<u>4,317</u>
	<u>37,345</u>	<u>22,925</u>

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

**Approved on behalf of the Board of Directors**

(signed) "James W. Hall", Director

(signed) "Wayne Pisano", Director

**IMV Inc.**

Unaudited Interim Condensed Consolidated Statements of Changes in Equity

**For the period ended June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

	Share Capital \$ (note 6)	Contributed Surplus \$ (note 7)	Warrants \$ (note 8)	Deficit \$	Total \$
<b>Balance, December 31, 2017</b>	70,113	6,375	674	(70,819)	6,343
Net loss and comprehensive loss for the period	–	–	–	(21,935)	(21,935)
Issuance of shares in public offering	14,375	–	–	–	14,375
Share issuance costs	(1,480)	–	–	–	(1,480)
Redemption of DSUs, net of applicable taxes	220	–	–	–	220
Issuance of broker warrants	–	–	332	–	332
Exercise of warrants	5,480	–	(591)	–	4,889
Employee share options:					
Value of services recognized	–	1,182	–	–	1,182
Exercise of options	1,444	(1,053)	–	–	391
<b>Balance, December 31, 2018</b>	90,152	6,504	415	(92,754)	4,317
Net loss and comprehensive loss for the period	–	–	–	(10,994)	(10,994)
Issuance of shares in public offering	29,456	–	–	–	29,456
Share issuance costs	(2,499)	–	–	–	(2,499)
Exercise of warrants	82	–	(21)	–	61
Warrants expired	–	62	(62)	–	–
Employee share options:					
Value of services recognized	–	694	–	–	694
Exercise of options	281	(225)	–	–	56
<b>Balance, June 30, 2019</b>	117,472	7,035	332	(103,748)	21,091

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

**IMV Inc.**

Unaudited Interim Condensed Consolidated Statements of Loss and Comprehensive Loss

**For the three and six months ended June 30, 2019 and 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>Revenue</b>				
Subcontract revenue	6	17	14	45
Interest revenue	180	112	254	181
	186	129	268	226
<b>Expenses</b>				
Research and development	3,803	2,605	7,816	4,487
General and administrative	2,184	2,640	4,144	3,930
Government assistance	(1,142)	(189)	(1,488)	(464)
Accreted interest (note 5)	392	269	790	536
	5,237	5,325	11,262	8,489
<b>Net loss and comprehensive loss for the year</b>	<b>(5,051)</b>	<b>(5,196)</b>	<b>(10,994)</b>	<b>(8,263)</b>
<b>Basic and diluted loss per share</b>	<b>(0.10)</b>	<b>(0.12)</b>	<b>(0.23)</b>	<b>(0.19)</b>
<b>Weighted-average shares outstanding</b>	<b>50,601,866</b>	<b>43,001,620</b>	<b>48,667,904</b>	<b>42,539,304</b>

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*



**IMV Inc.**

Unaudited Interim Condensed Consolidated Statements of Cash Flows

**For the six months ended June 30, 2019 and 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

	<b>Six months ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
<b>Cash provided by (used in)</b>		
<b>Operating activities</b>		
Net loss and comprehensive loss for the year	(10,994)	(8,263)
Charges to operations not involving cash		
Interest on lease obligation	76	17
Depreciation of property and equipment	225	99
Accretion of long-term debt	790	536
Deferred share unit compensation	(390)	113
Stock-based compensation	694	496
Loss on disposal of assets	1	–
Revaluation of long-term debt	(840)	–
	<u>(10,438)</u>	<u>(7,002)</u>
Net cash flows used by operation activities before changes in non-cash working capital items	(10,438)	(7,002)
Net change in non-cash working capital balances related to operations		
Decrease (increase) in amounts receivable	52	(101)
Increase in prepaid expenses	(338)	(904)
Increase in investment tax credits receivable	(639)	(62)
(Decrease) increase in accounts payable and accrued liabilities	(3,148)	941
Increase in amounts due to directors	14	1
	<u>(14,497)</u>	<u>(7,127)</u>
<b>Financing activities</b>		
Proceeds from public offering	29,456	14,375
Share issuance costs in public offering	(2,499)	(1,148)
Proceeds from the exercise of stock options	56	186
Proceeds from the exercise of warrants	61	4,477
Withholdings on redemption of DSUs	–	(97)
Repayment of long-term debt	(42)	(34)
Repayment of lease obligation	(120)	(9)
	<u>26,912</u>	<u>17,750</u>
<b>Investing activities</b>		
Acquisition of property and equipment	(406)	(733)
Incentive contribution from lessor	–	349
	<u>(406)</u>	<u>(384)</u>
<b>Net change in cash and cash equivalents during the period</b>	<b>12,009</b>	<b>10,239</b>
<b>Cash and cash equivalents – Beginning of period</b>	<b>14,895</b>	<b>14,909</b>
<b>Cash and cash equivalents – End of period</b>	<b>26,904</b>	<b>25,148</b>
<b>Supplementary cash flow</b>		
Interest received	254	181

*The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.*

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**(Expressed in thousands of Canadian dollars except for per share amounts)

---

**1 Nature of operations**

IMV Inc. (the “Corporation”, “IMV”) is, through its 100% owned subsidiary, a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer. IMV is pioneering a new class of immunotherapies based on the Corporation’s proprietary drug delivery platform (“DPX”). This patented technology does not release the active ingredients at the site of injection but forces an active uptake and delivery of active ingredients into immune cells and lymph nodes. The Corporation’s first cancer immunotherapy uses survivin based peptides licensed from Merck KGaA, on a worldwide exclusive basis, formulated in DPX (“DPX-Survivac”). DPX-Survivac, has demonstrated the ability to induce prolonged T cell activation leading to tumour regressions in advanced ovarian cancer and is currently being used in clinical trials as a monotherapy and in combination with Merck’s KEYTRUDA® checkpoint inhibitor. The Corporation has one reportable and geographic segment. Incorporated under the Canada Business Corporations Act and domiciled in Dartmouth, Nova Scotia, the shares of the Corporation are listed on the Nasdaq Stock Market and the Toronto Stock Exchange under the symbol “IMV”. The address of its principal place of business is 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia, Canada.

**2 Basis of presentation**

The Corporation prepares its unaudited interim condensed consolidated financial statements in accordance with Canadian generally accepted accounting principles as set out in the Chartered Professional Accountants of Canada Handbook – Accounting Part I, which incorporates International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

These unaudited interim condensed consolidated financial statements have been prepared in accordance with IFRS applicable to the preparation of interim financial statements, including IAS 34, International Accounting Standards 34 “*Interim Financial Reporting*”. Accordingly, certain information normally included in annual audited financial statements prepared in accordance with IFRS, as issued by the IASB, have been omitted or condensed. The unaudited interim condensed consolidated financial statements should be read in conjunction with the Corporation’s annual audited consolidated financial statements for the year ended December 31, 2018.

**3 Significant accounting policies, judgements and estimation uncertainty**

These unaudited interim condensed consolidated financial statements have been prepared using the same policies and methods as the annual audited consolidated financial statements of the Corporation for the period ended December 31, 2018. Refer to note 4 of the Corporation’s annual audited consolidated financial statements for the year ended December 31, 2018 for more information on accounting policies and methods applied.

(2)

---

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**4 Deferred share units (“DSUs”)**

The maximum number of common shares which the Corporation is entitled to issue from Treasury in connection with the redemption of DSUs granted under the DSU Plan is 468,750 common shares.

DSU activity for the three months ended June 30, 2019 and the year ended December 31, 2018 are as follows:

	<b>June 30, 2019 Number</b>	<b>December 31, 2018 Number</b>
<b>Opening balance</b>	223,604	186,330
Granted	63,368	97,072
Redeemed	–	(59,798)
<b>Closing balance</b>	<b>286,972</b>	<b>223,604</b>

As at June 30, 2019, there were 286,972 (2018 - 223,604) DSUs outstanding related to this Plan and the total carrying amount of the liability was \$1,046 (2018 - \$1,436). The compensation expense (recovery) at June 30, 2019 was (\$390) (2018 - \$508 expense), recognized over the vesting period. Vested DSUs cannot be redeemed until the holder is no longer a member of the Board. The redemption value of a DSU equals the market value of an IMV Inc. common share at the time of redemption. On an ongoing basis, the Corporation values the DSU obligation at the current market value of a corresponding number of IMV Inc. common shares and records any increase or decrease in the DSU obligation as an expense on the consolidated statements of loss and comprehensive loss.

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**5 Long-term debt**

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
	\$	\$
Atlantic Canada Opportunities Agency (“ACOA”) Atlantic Innovation Fund interest-free loan with a maximum contribution of \$3,786. Annual repayments, commencing December 1, 2008, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than \$5,000 and 5% when gross revenues are greater than \$5,000. As at June 30, 2019, the amount drawn down on the loan, net of repayments, is \$3,744 (2018 - \$3,744).	1,412	1,202
ACOA Atlantic Innovation Fund interest-free loan with a maximum contribution of \$3,000. Annual repayments, commencing December 1, 2011, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than \$5,000 and 5% when gross revenues are greater than \$5,000. As at June 30, 2019, the amount drawn down on the loan is \$2,995 (2018 - \$2,995).	1,276	1,034
ACOA Business Development Program, interest-free loan with a maximum contribution of \$395, repayable in monthly payments beginning October 2015 of \$3 until October 2017 and \$6 until September 2022. As at June 30, 2019, the amount drawn down on the loan, net of repayments, is \$218 (2018 - \$251).	209	238
ACOA Atlantic Innovation Fund interest-free loan with a maximum contribution of \$2,944, annual repayments commencing September 1, 2014, are calculated as a percentage of gross revenue from specific product(s) for the preceding fiscal year, at 5% for the first 5 year period and 10%, thereafter. As at June 30, 2019, the amount drawn down on the loan is \$2,944 (2018 - \$2,944).	1,125	957
TNC 120-140 Eileen Stubbs Ltd. (the “Landlord”) loan of \$300,000, bearing interest at 8% annum, is repayable in monthly payments beginning upon receipt of the final installment of the loan until May 31, 2028. The loan is made available in three equal installments based on the Corporation meeting certain milestones. As at June 30, 2019, the amount drawn down on the loan is \$291 (2018 - \$300).	291	300
Province of Nova Scotia “The Province” secured loan with a maximum contribution of \$5,000, interest bearing at a rate equal to the Province’s cost of funds plus 1%, compounded semi-annually and payable monthly. The loan is repayable in monthly payments beginning January 1, 2021 of \$83 plus interest until December 2025. The Corporation and its subsidiary have provided a general security agreement granting a first security interest in favour of the Province of Nova Scotia in and to all the assets of the Corporation and its subsidiary, including the intellectual property. As at June 30, 2019, the amount drawn down on the loan is \$5,000 (2018 - \$5,000).	3,745	4,419
	<u>8,058</u>	<u>8,150</u>
Less: Current portion	86	81
	<u>7,972</u>	<u>8,069</u>

(4)

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**5 Long-term debt (continued)**

Total contributions received, less amounts that have been repaid as at June 30, 2019, is \$15,192 (2018 - \$15,234).

Certain ACOA loans and the Province loan require approval by ACOA or the Minister for the Province before the Corporation can pay management fees, bonuses, dividends or other distributions, before there is any change of ownership of the Corporation. The Province loan requires the Corporation to obtain the written consent of the Province prior to the sale, disposal or abandonment of possession of the intellectual property of the Corporation or its subsidiary. If during the term of the Province loan, the head office, research and development facilities, or production facilities of the Corporation are moved from the Province, the Corporation is required to repay 40% of the outstanding principal of the loan.

In June 2019, the Corporation amended its loan agreement with the Province. Previously, the maturity date of the loan was August 9, 2020. The Corporation shall now start repaying the balance of the principal amount on the first day of January 2021, by making 60 monthly principal payments of \$83 plus interest from January 2021 to December 2025. The annual interest rate remains at the Province's cost of funds plus 1%.

In accounting for this change, the Corporation determined, based on industry risk, its own credit risk and the interest rate environment, that the effective interest rate of the loan of 11% remains appropriate. The difference between the carrying value of the loan before the amendment and after the amendment of \$840 has been recorded in the statement of loss and comprehensive loss as government assistance.

The Province loan requires certain early repayments if the Corporation's subsidiary, or the Corporation on a consolidated basis, has cash flow from operations in excess of \$1,500. The Province loan also requires repayment of the loan under certain circumstances, such as changes of control, sale or liquidation of the Corporation or the sale of substantially all of the assets of the Corporation.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
	<b>\$</b>	<b>\$</b>
<b>Balance – Beginning of year</b>	8,150	6,537
Borrowings, net of \$nil (2018 - \$nil) allocated to government assistance	–	300
Accreted interest	790	1,385
Revaluation of long-term debt	(840)	–
Repayment of debt	(42)	(72)
<b>Balance – End of year</b>	<b>8,058</b>	<b>8,150</b>
Less: Current portion	86	81
Non-current portion	<u>7,972</u>	<u>8,069</u>

The Corporation is in compliance with its debt covenants.

(5)

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**6 Share capital****Authorized**

Unlimited number of common shares and preferred shares, issuable in series, all without par value.

	Number of common shares #	Amount \$
<b>Issued and outstanding</b>		
<b>Balance – December 31, 2017</b>	40,319,941	70,113
Issued for cash consideration, net of issuance costs	2,246,094	12,895
Stock options exercised	480,754	1,444
DSUs redeemed	29,713	220
Warrants exercised	2,029,899	5,480
<b>Balance – December 31, 2018</b>	<b>45,106,401</b>	<b>90,152</b>
Issued for cash, net of issuance costs	5,404,855	26,957
Stock options exercised	86,446	281
Warrants exercised	14,423	82
<b>Balance – June 30, 2019</b>	<b>50,612,125</b>	<b>117,472</b>

As at June 30, 2019, a total of 2,041,251 shares (2018 - 1,890,539) are reserved to meet outstanding stock options, warrants and deferred share units.

On March 6, 2019, the Corporation completed a public offering, issuing an aggregate of 4,900,000 common shares at a price of \$5.45 per common share, raising gross proceeds of \$26,705. On March 11, 2019, the underwriters partially exercised their option to purchase common shares, resulting in the issuance of 504,855 common shares of the Corporation at a price of \$5.45 per share for additional gross proceeds of approximately \$2,751. As a result of the exercise of this option, the Corporation has raised total gross proceeds of approximately \$29,456 before deducting the underwriting commissions and offering expenses of \$2,499.

On February 15, 2018, the Corporation completed a bought deal public offering of 2,246,094 common shares at a price of \$6.40 per common share, for aggregate proceeds of \$14,375. Total costs associated with the offering were \$1,480, including cash costs for commissions of \$863, professional fees and regulatory costs of \$285, and 134,766 compensation warrants issued as commissions to the agents valued at \$332. Each compensation warrant entitles the holder to acquire one common share of the Corporation at an exercise price of \$6.53 for a period of 24 months, expiring on February 15, 2020.

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**7 Contributed surplus****Amount  
\$****Contributed surplus**

<b>Balance – December 31, 2017</b>	6,375
Share-based compensation – stock options vested	1,182
Stock options exercised	(1,053)
<b>Balance – December 31, 2018</b>	6,504
Share-based compensation – stock options vested	694
Stock options exercised	(225)
Warrants expired	62
<b>Balance – June 30, 2019</b>	<u>7,035</u>

**Stock options**

The fair values of stock options are estimated using the Black-Scholes option pricing model. In the current year, 243,100 stock options (2018 - 619,505) with a weighted average exercise price of \$7.39 (2018 - \$6.65) and a term of five years (2018 - five years), were granted to employees. The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued. The value of these stock options has been estimated at \$909 (2018 - \$2,378), which is a weighted average grant date value per option of \$3.74 (2018 - \$3.84), using the Black-Scholes valuation model and the following weighted average assumptions:

	<b>2019</b>	<b>2018</b>
Risk-free interest rate	1.89%	2.02%
Expected volatility	64%	77%
Expected life (years)	4.2	4.2
Forfeiture rate	5%	5%

Option activity for the six months ended June 30, 2019 and the year ended December 31, 2018 was as follows:

	<b>June 30, 2019</b>		<b>December 31, 2018</b>	
	<b>Number</b>	<b>Weighted average exercise price \$</b>	<b>Number</b>	<b>Weighted average exercise price \$</b>
<b>Outstanding – Beginning of year</b>	1,474,477	4.12	1,498,052	2.26
Granted	243,100	7.39	619,505	6.65
Exercised	(121,127) <sup>1</sup>	2.35	(626,875) <sup>1</sup>	2.18
Expired	(12,500)	2.37	(5,569)	1.80
Forfeited	(7,706)	7.13	(10,636)	4.92
<b>Outstanding – End of year</b>	<u>1,576,244</u>	4.76	<u>1,474,477</u>	4.12

1 Of the 121,127 (2018 - 626,875) options exercised, 98,408 (2018 - 443,748) elected the cashless exercise, under which 63,727 shares (2018 - 297,626) were issued. These options would have otherwise been exercisable for proceeds of \$229 (2018 - \$975) on the exercise date.

(7)

**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**7 Contributed surplus (continued)****Stock options (continued)**

The weighted average exercise price of options exercisable at June 30, 2019 was \$3.22 (2018 - \$4.09).

The maximum number of common shares issuable under the Corporation's stock option plan shall not exceed 4,600,000 inclusive of all shares presently reserved for issuance pursuant to previously granted stock options.

**8 Warrants**

Warrant activity for the period ended June 30, 2019 and the year ended December 31, 2018 was as follows:

	<b>June 30, 2019</b>			<b>December 31, 2018</b>		
	<b>Number</b>	<b>Weighted average exercise price \$</b>	<b>Amount \$</b>	<b>Number</b>	<b>Weighted average exercise price \$</b>	<b>Amount \$</b>
<b>Opening balance</b>	192,459	5.84	415	2,087,598	2.46	674
Granted	–	–	–	134,766	6.53	332
Exercised	(14,423)	4.22	(21)	(2,029,905)	2.41	(591)
Expired	(43,269)	4.22	(62)	–	–	–
<b>Closing balance</b>	<b>134,767</b>	<b>6.53</b>	<b>332</b>	<b>192,459</b>	<b>5.84</b>	<b>415</b>

The fair values of warrants are estimated using the Black-Scholes option pricing model. There have been no warrants issued to date in 2019. The weighted average assumptions used in the Black-Scholes valuation model for the periods presented were as follows:

	<b>2018</b>
Risk-free interest rate	1.84%
Expected volatility	68%
Expected dividend yield	–
Expected life (years)	2

(8)



**IMV Inc.**

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

**As at June 30, 2019 and December 31, 2018**

(Expressed in thousands of Canadian dollars except for per share amounts)

**9 Financial instruments****Fair value of financial instruments**

Financial instruments are defined as a contractual right or obligation to receive or deliver cash on another financial asset.

The following table sets out the approximate fair values of financial instruments as at the consolidated statements of financial position date with relevant comparatives:

	<b>June 30, 2019</b>		<b>December 31, 2018</b>	
	<b>Carrying value</b>	<b>Fair value</b>	<b>Carrying value</b>	<b>Fair value</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Cash and cash equivalents	26,904	26,904	14,895	14,895
Amounts receivable	1,285	1,285	780	780
Accounts payable and accrued liabilities	5,720	5,720	7,557	7,557
Amounts due to directors	63	63	49	49
Long-term debt	7,972	7,972	8,069	8,069

Assets and liabilities, such as commodity taxes, that are not contractual and that arise as a result of statutory requirements imposed by governments, do not meet the definition of financial assets or financial liabilities and are, therefore, excluded from amounts receivable and accounts payable.

Fair value of items, which are short-term in nature, have been deemed to approximate their carrying value. The above noted fair values, presented for information only, reflect conditions that existed only at June 30, 2019 and December 31, 2018 and do not necessarily reflect future value or amounts which the Corporation might receive if it were to sell some or all of its assets to a willing buyer in a free and open market.

The fair value of the long-term debt is estimated based on the expected interest rates for similar borrowings by the Corporation at the consolidated statements of financial position dates. At June 30, 2019, the fair value is estimated to be equal to the carrying amount.

**10 Related party transactions**

During the six months ended June 30, 2019, there were no related party transactions (2018 - \$nil).

(9)



**Management's Report on Financial Position and Operating Results**

**For the three and six-months ended June 30, 2019**

---

## LETTER TO SHAREHOLDERS

Dear Fellow Shareholders,

In the second quarter, we reported important updates from two Phase 2 studies of our lead program, DPX-Survivac. These results continue to validate our DPX platform and this novel target, with encouraging signs of anti-tumour activity contributing to the body of data we have accumulated to demonstrate DPX-Survivac's potential in hard-to-treat cancers, both as a monotherapy and in combination with other agents. We look forward to providing additional data from these programs by year-end, including top-line results from our Phase 2 study evaluating DPX-Survivac as a monotherapy in ovarian cancer and additional results from our Phase 2 relapsed/refractory DLBCL and the basket trial, evaluating DPX-Survivac in combination with Keytruda in multiple solid tumour indications.

### **DPX-Survivac Clinical Program Updates:**

- *Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable clinical benefit with progression-free survival in patients with advanced recurrent ovarian cancer*
- *Reported positive new data from Phase 2 SPiReL combination study of DPX-Survivac in r/r DLBCL, including long-lasting complete responses*
- *The 16 additional patients in the advanced recurrent ovarian cancer monotherapy arm of the Phase 1b/2 DeCidE1 Clinical Study are enrolled*
- *Additional data expected from three Phase 2 studies of DPX-Survivac by year-end, including as monotherapy in ovarian cancer and as combination therapy in r/r DLBCL and multiple other solid tumor types*

### **Phase 1b/2 DeCidE1 Clinical Study in Advanced Recurrent Ovarian Cancer**

In June 2019, we presented new data at the 2019 American Society of Clinical Oncology (ASCO) annual meeting from DeCidE1, our ongoing Phase 1b/2 study evaluating the safety and efficacy of DPX-Survivac and intermittent low-dose cyclophosphamide (CPA), with and without epacadostat, in advanced recurrent ovarian cancer. These results expand on data previously reported from this study, which exhibited a durable response. Highlights of the new data from evaluable patients in the Phase 2 monotherapy arm of the trial include:

- Five out of seven patients showed signs of treatment benefits, including reduction of target lesions in two patients;
- Three out of four patients with low tumour burden showed stable disease, including two with tumour regression at first CT scan;
- Of the five patients evaluable for T cell responses, all showed survivin-specific T cell activation in the blood; and
- Treatments were well-tolerated supporting our views of the favourable safety profile of our approach.

Additionally, longer-term follow-up data from the Phase 1b portion of the study continued to demonstrate the prolonged duration of clinical benefits, surpassing two years of progression-free survival from previous treatments, including platinum-based chemotherapy, and that levels of survivin-specific T cells in the blood of patients continue to correlate with this effect. Sixteen additional patients have been enrolled in the expanded monotherapy arm of DeCidE1 trial. IMV expects to provide the top-line clinical results from this study before the end of 2019.

### **Phase 2 SPiReL Study of DPX-Survivac in Combination with KEYTRUDA® in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)**

In June 2019, IMV reported updated data from SPiReL, its ongoing investigator-sponsored Phase 2 clinical trial assessing DPX-Survivac in combination with intermittent low dose cyclophosphamide and Merck's checkpoint inhibitor Keytruda, linking antitumour activity with T cell responses that correlate with expression of survivin.

At the first "on treatment" interim assessment, five of the first six patients demonstrated clinical benefit, including four patients with tumour regressions. Two patients reached a complete radiological response, one exhibited a partial response and two reached stable disease while on the study. In addition, the study continued to demonstrate an acceptable safety profile for the two therapies in combination.

Based on these data, IMV agreed with the principal investigator to increase the number of sites recruiting patients from 5 up to 9. As of August 8, 2019, investigators had enrolled 12 patients across four different clinical sites in Canada. Additional patients are being screened and IMV expects to give another update on this trial before the end of 2019 and report top-line clinical data from this study in the first half of 2020.

### **Phase 2 Basket Trial of DPX-Survivac in Combination with KEYTRUDA® in Multiple Solid Tumour Indications**

---

Fifteen patients have been enrolled to date, while screening and enrollment of patients is ongoing across nine clinical sites in the U.S. and Canada for five cohorts of patients with bladder, liver (hepatocellular carcinoma), ovarian, or non-small cell lung (NSCLC) cancers, as well as tumours shown to be positive for the microsatellite instability high (MSI-H) biomarker. Also, there are nine site initiation visits that are already scheduled that will bring the total of active sites to 18. Patients have been treated in every cohort and IMV expects to report preliminary clinical results on several of the solid tumour indications included in this basket trial before the end of 2019.

**Operational Highlights:**

**Modification of \$5M loan agreement with the province of Nova Scotia**

Previously, the entire loan was payable on August 9, 2020. Per this modification, the Corporation will now repay the loan over 60 months starting in January 2021. This revised repayment schedule will allow IMV to devote its cash resources towards development of its clinical programs. All the other terms remain the same.

**The following table indicates IMV expected milestones between now and the first half of 2020:**

Preliminary clinical results Basket trial in 5 indications	H2 2019
Topline monotherapy clinical results in Ovarian	H2 2019
Clinical results update in the DLBCL combination trial (investigator-sponsored)	H2 2019
Top-line clinical results in the DLBCL combination trial (investigator-sponsored)	H1 2020
Top line clinical results for Basket trial	H1 2020

With multiple phase 2 trials ongoing in six different indications both as monotherapy and in combination with Merck's Keytruda we are successfully developing one of the most advanced and comprehensive clinical pipelines in immuno-oncology.

So far in 2019, we delivered promising preliminary clinical results highlighting the potential of our targeted T cell therapy in hard-to-treat solid and blood tumours. As we are approaching the phase 2 inflexion point our teams are now focusing on preparation for the next stage of growth to move into pivotal trials in 2020 to support our first market approvals. This is an intensive period of time operationally for manufacturing, clinical, regulatory/quality, pre-marketing and business development and our team is enthusiastic to achieve these goals.

We believe our first-in-class targeted T cell therapy has the potential to offer an unprecedented combination of a favorable safety/tolerability profile with long-lasting clinical benefits and we are committed to bring this new treatment option to cancer patients with a sense of urgency.

We are grateful for the continued support of our shareholders and partners and look forward to a very productive remainder of 2019.

*/s/ Frederic Ors*  
Frederic Ors  
Chief Executive Officer



## MANAGEMENT DISCUSSION AND ANALYSIS (“MD&A”)

The following analysis provides a review of the unaudited interim condensed consolidated results of operations, financial condition, and cash flows for the three and six months period ended June 30, 2019 (“Q2 2019”), with information compared to the three and six months ended June 30, 2018 (“Q2 2018”), for IMV Inc. (“IMV” or the “Corporation”). This analysis should also be read in conjunction with the information contained in the annual audited consolidated financial statements and related notes for the years ended December 31, 2018 and December 31, 2017.

The Corporation prepares its unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (IASB). Management is responsible for the preparation of the consolidated financial statements and other financial information relating to the Corporation included in this report. The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting. In furtherance of the foregoing, the Board of Directors has appointed an Audit Committee comprised of independent directors. The Audit Committee meets with management and the auditors in order to discuss the results of operations and the financial condition of the Corporation prior to making recommendations and submitting the consolidated financial statements to the Board of Directors for its consideration and approval for issuance to shareholders. The information included in this MD&A is as of August 8, 2019, the date when the Board of Directors approved the Corporation’s unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2019, on the recommendation of the Audit Committee.

Amounts presented in this MD&A are approximate and have been rounded to the nearest thousand except for per share data. Unless specified otherwise, all amounts are presented in thousands of Canadian dollars.

Additional information regarding the business of the Corporation, including the Annual Information Form of the Corporation for the year ended December 31, 2018 (the “AIF”) and included in the Corporation’s registration statement on Form 40-F filed with the U.S. Securities and Exchange Commission, is available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

## FORWARD-LOOKING STATEMENTS

Certain statements in this MD&A may constitute “forward-looking” statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Corporation, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. When used in this MD&A, such statements use such words as “will”, “may”, “could”, “intends”, “potential”, “plans”, “believes”, “expects”, “projects”, “estimates”, “anticipates”, “continue”, “potential”, “predicts” or “should” and other similar terminology. These statements reflect current expectations of management regarding future events and operating performance and speak only as of the date of this MD&A. Forward-looking statements include, among others:

- The Corporation’s business strategy;
- Statements with respect to the sufficiency of the Corporation’s financial resources to support its activities;
- Potential sources of funding;
- The Corporation’s ability to obtain necessary funding on favorable terms or at all;
- The Corporation’s expected expenditures and accumulated deficit level;
- The Corporation’s expected outcomes from its ongoing and future research and research collaborations;
- The Corporation’s exploration of opportunities to maximize shareholder value as part of the ordinary course of its business through collaborations, strategic partnerships, and other transactions with third parties;
- The Corporation’s plans for the research and development of certain product candidates;
- The Corporation’s strategy for protecting its intellectual property;
- The Corporation’s ability to identify licensable products or research suitable for licensing and commercialization;
- The Corporation’s ability to obtain licences on commercially reasonable terms;
- The Corporation’s plans for generating revenue;
- The Corporation’s plans for future clinical trials; and
- The Corporation’s hiring and retention of skilled staff.

Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements, including, but not limited to, the factors discussed in the AIF, under the heading “Risk Factors and Uncertainties.” Although the forward-looking statements contained in this MD&A are based upon what management of the Corporation believes are reasonable assumptions, the Corporation cannot provide any assurance to investors that actual results will be consistent with these forward-looking statements and should not be unduly relied upon by investors.

Actual results, performance and achievements are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this MD&A. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about:

- Obtaining additional funding on reasonable terms when necessary;
- Positive results of pre-clinical studies and clinical trials;
- The Corporation’s ability to successfully develop existing and new products;
- The Corporation’s ability to hire and retain skilled staff;
- The products and technology offered by the Corporation’s competitors;
- General business and economic conditions;
- The Corporation’s ability to protect its intellectual property;
- The Corporation’s ability to manufacture its products and to meet demand; and
- Regulatory approvals.

These statements reflect management’s current views and beliefs and are based on estimates, assumptions, and information currently available to, and considered reasonable by, management. The information contained herein is dated as of August 8, 2019, the date of the Board’s approval of the Q2 2019 unaudited interim condensed consolidated financial statements and of the MD&A. For additional information on risks, uncertainties, and assumptions, including a more detailed assessment of the risks that could cause actual results to materially differ from current expectations, please refer to the AIF of IMV filed on SEDAR at [www.sedar.com](http://www.sedar.com) and included in the registration statement on Form 40-F filed on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

## CORPORATE OVERVIEW

IMV is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Corporation’s proprietary drug delivery platform (“**DPX**”). This patented technology leverages a novel mechanism of action (“**MOA**”) discovered by the Corporation. This MOA does not release the active ingredients at the site of injection but forces an active uptake and delivery of active ingredients into immune cells and lymph nodes. It enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. DPX’s no-release MOA can be leveraged to generate “first-in-class” T cell therapies with the potential, in the opinion of IMV, to be transformative in the treatment of cancer.

The Corporation’s first cancer immunotherapy uses survivin-based peptides licensed from Merck KGaA, on a world-wide exclusive basis, formulated in DPX (“**DPX-Survivac**”). Survivin is a well characterized and tumour associated antigen known to be overexpressed in more than 20 different cancers. DPX-Survivac leverages the MOA of DPX to generate a constant flow of T cells in the blood that are targeted against survivin expressed on cancer cells. It is comprised of five minimal MHC class I peptides to activate naïve T cells against survivin.

DPX-Survivac is currently being tested in:

- A phase 2 clinical trial that evaluates DPX-Survivac in an open label safety and efficacy study in ovarian cancer patients with advanced platinum-sensitive and resistant ovarian cancer;
- Two investigator-sponsored phase 2 clinical trials in combination with the checkpoint inhibitor Keytruda® (pembrolizumab) of Merck & Co Inc. (“Merck”) in patients with recurrent, platinum-resistant, and sensitive ovarian cancer and in patients with measurable or recurrent diffuse large B cell lymphoma (“DLBCL”); and

- A phase 2 basket trial in combination with Merck’s Keytruda® (pembrolizumab) in patients with select advanced or recurrent solid tumours in bladder, liver (hepatocellular carcinoma), ovarian, or non-small-cell lung (NSCLC) cancers, as well as tumours shown to be positive for the microsatellite instability high (MSI-H) biomarker.

In infectious disease vaccine applications, the Corporation has completed a demonstration phase 1 clinical trial with a target against the respiratory syncytial virus (“RSV”). The Corporation also has a commercial licensing agreement with Zoetis for the development of two cattle vaccines and is also conducting several research and clinical collaborations, including a collaboration with the Dana-Farber Cancer Institute (“Dana-Farber”) for Human Papillomavirus (“HPV”) related cancers and with Leidos, Inc. (“Leidos”) in the United States for the development of vaccine candidates for malaria and the Zika virus.

The common shares of the Corporation are listed on the Nasdaq Stock Market LLC and on the Toronto Stock Exchange under the symbol “IMV”.

## **BUSINESS MODEL AND STRATEGY**

IMV is dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer. The Corporation’s lead product candidate, DPX-Survivac, has demonstrated the ability to induce prolonged T cell activation leading to tumour regressions in advanced ovarian cancer and is currently being used in clinical trials as a monotherapy and in combination with Merck’s KEYTRUDA® checkpoint inhibitor.

Foremost, the Corporation’s clinical strategy is to establish monotherapy activity of DPX-Survivac in order to increase value, de-risk clinical development, and to target late stage unmet medical needs for a shorter path to clinical demonstration and first regulatory approval and to establish strategic partnerships to support further development and commercialization. In addition, the Corporation is evaluating DPX Survivac in combination with Merck’s KEYTRUDA® checkpoint inhibitor in multiple oncology targets.

The Corporation is focusing on a fast path to market in ovarian and diffuse large DLBCL cancers and on repeating its clinical demonstrations of activity in other indications.

In collaboration with commercial and academic partners, the Corporation is also expanding the application of DPX as a delivery platform for other applications. Pre-clinical and clinical studies have indicated to date that the Corporation’s delivery platform may allow for the development of enhanced vaccines for a wide range of infectious diseases by generating a stronger and more durable immune response than is possible with existing delivery methods.

The Corporation intends to be opportunistic in the development of products by exploring a variety of avenues, including co-development through potential collaborations, strategic partnerships or other transactions with third parties. The Corporation may seek additional equity and non-dilutive funding and partnerships to advance the development of its product candidates.

## **PLATFORM AND PRODUCTS IN DEVELOPMENT**

### ***Delivery Platform***

The DPX platform is a unique and patented formulation discovered by the Corporation that provides a new way to deliver active ingredients to the immune system using a novel MOA. This MOA does not release the active ingredients at the site of injection but forces an active uptake and delivery of active ingredients into immune cells and lymph nodes. IMV is exploiting this MOA to pioneer a new class of immunotherapies that represents a paradigm shift from current approaches. By not releasing the active ingredients at the site of injection, it bypasses the steps involved in conventional immune “native responses,” such as vaccines, and enables access and programming of immune cells *in-vivo* to generate new “synthetic” therapeutic capabilities. The DPX no-release MOA can be leveraged to generate “first-in-class” T cell therapies with the potential to be transformative in the treatment of cancer. The Corporation believes that the novel MOA of DPX makes the platform uniquely suitable for



cancer immunotherapies, which are designed to target tumour cells. DPX can induce prolonged, target-specific, and polyfunctional T cell activation, which are postulated to be required for effective tumour control.




Figure 1: Illustrative representation of IMV's DPX new MOA

The DPX platform is based on active ingredients formulated in lipid nanoparticles and, after freeze drying, suspended directly into oil. DPX-based products are stored in a dry format, which provides the added benefit of an extended shelf life. The formulation is designed to be easy to re-suspend and administer to patients.

DPX also has multiple manufacturing advantages: it is fully synthetic; can accommodate hydrophilic and hydrophobic compounds; is amenable to a wide-range of applications (for example, peptides, small-molecules, RNA/DNA, or antibodies); and provides long term stability as well as low cost of goods.

The DPX platform forms the basis of all of IMV's product development programs.

**DPX-Survivac**

*Product Candidate Overview*

Cancer	Survivin %
Ovarian	90
Breast	90
Melanoma	90
Lung	53
Colorectal	54
Gastric	94
Kidney	23-82
Glioblastoma	80
ALL	70
CML	70
MDS	90
DLBCL	60

Figure 2: Examples of % of patients with survivin expression in different indications

DPX-Survivac, the Corporation's first cancer immunotherapy candidate, uses survivin-based peptides licensed from Merck KGaA on a world-wide exclusive basis that are formulated in DPX. DPX-Survivac leverages the MOA of DPX to generate a constant flow of T cells in the blood that are targeted against survivin expressed on cancer cells and is comprised of five minimal MHC class I peptides to activate naïve T cells against survivin.

Survivin is a well characterized and recognized tumour associated antigen known to be expressed during fetal development and across most tumour cell types, but it is rarely present in normal non-malignant adult cells. Survivin controls key cancer processes (apoptosis, cell division, and metastasis) and has been associated with chemoresistance and cancer progression. It has been shown that survivin was expressed in all 60 different human tumour lines used in the National Cancer Institute's cancer drug screening program and is documented in the literature to be overexpressed in more than 20 indications.

**IMMUNO-ONCOLOGY**

DPX-Survivac is being tested in 6 different cancer indications through multiple phase 2 clinical trials.

## Ongoing Clinical Trials

T cell therapy	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Sponsor	Collaborators
DPX-Survivac (Survivin)	Ovarian - monotherapy					IMV™	
	DLBCL Combination with Keytruda®					Sunnybrook UNIVERSITY HEALTH SCIENCES CENTRE	MERCK
	Lung (NSCLC) Combination with Keytruda®					IMV™	MERCK
	Bladder Combination with Keytruda®					IMV™	MERCK
	MSI-H Combination with Keytruda®					IMV™	MERCK
	Liver (HCC) Combination with Keytruda®					IMV™	MERCK
	Ovarian Combination with Keytruda®					IMV™	MERCK
	Ovarian Combination with Keytruda®					IMV™	MERCK
	Ovarian Combination with Keytruda®					UHN University Health Network Toronto General Hospital	MERCK
	DPX-SurMAGE (Survivin + MAGE A8)	Bladder					IMV™

### DPX-Survivac – Ongoing Clinical Trials

#### Monotherapy

##### *Ovarian subpopulation – DeCidE1 phase 1b/2*

The DeCidE1 (DPX-Survivac with low dose intermittent cyclophosphamide) phase 1b/2 study is an open label safety and efficacy study for individuals with recurrent advanced platinum-sensitive and resistant ovarian cancer. The phase 2 monotherapy arm of the DeCidE1 trial added an additional 16 patients in the population with a lower tumour burden. IMV expects to provide the top-line clinical results from this study before the end of 2019. Primary and secondary end points include:

- Safety profile;
- Objective Response Rate (“ORR”) and Duration of Response (“DOR”) using Recist 1.1 criteria;
- Induction of systemic survivin-specific T-cells in the blood; and
- Induction of T-cell infiltration into tumours.

On June 3, 2019, investigators shared new positive data for IMV Inc.'s DeCidE1 clinical trial at the 2019 American Society for Clinical Oncology (ASCO) annual meeting.

New data from evaluable patients from the phase 2 monotherapy arm of the trial indicated the potential for DPX-Survivac to impact solid tumour growth in hard-to-treat ovarian cancer patients. Longer-term follow-up from the phase 1b portion of the

trial continued to demonstrate that the levels of survivin-specific T cells in the blood of patients- a measure of DPX-Survivac's novel mechanism of action- correlated with durable clinical benefits.

In a poster presentation, Dr. Janos L. Tanyi, MD, PhD, assistant professor of obstetrics and gynecology at the Hospital of the University of Pennsylvania, provided an update on the clinical results from the first patients enrolled in the phase 2 monotherapy cohort:

- Of seven patients evaluable at data cut-off in the monotherapy arm, five showed signs of treatment benefits, including reduction of target lesions in two patients, while two patients progressed;
- Within the group of four patients with low tumour burden -- a potential predictor of response -- three showed stable diseases including two reductions in tumour burden continuing the positive trend seen in earlier results;
- All subjects evaluable for T cell responses (five of five) showed survivin specific T cell activation in the blood. Immunohistochemistry (“IHC”) analysis for tumour infiltration is continuing; and
- Treatments have been well tolerated.

The data also highlighted long-lasting responders from the phase 1b portion of the study with key takeaways as follows:

- Prolonged duration of clinical benefits reaching up to more than two years, surpassing the progression-free survival to previous treatments, including platinum-based chemotherapy;
- Long-lasting clinical benefits and high levels of survivin specific T cells are associated with long-term treatment;
- One subject has received DPX-Survivac for more than 21 months so far. This finding is the longest duration of treatment for DPX-Survivac on record to date; and
- It is supportive of DPX Survivac's ability to maintain high levels of survivin-specific T cells in the blood over a prolonged period of time.

In December, 2018, IMV met with the U.S. Food and Drug Administration (“FDA”) in a Type B meeting to discuss the results to date of its DeCide1 clinical trial and continuing development plan, as well as to obtain agency guidance on a potential accelerated regulatory pathway for DPX-Survivac as a T cell immunotherapy for the treatment of advanced ovarian cancer in patients with progressing disease.

The purpose of IMV's Type B meeting with the FDA was to request feedback on the design of the clinical program for DPX-Survivac. This program includes the continuing DeCide1 phase 2 clinical study and a potential future registration trial for accelerated approval in a subset of ovarian cancer patients.

The FDA reviewed the Corporation’s proposed clinical development plan and acknowledged the potential for accelerated approval in advanced ovarian cancer based on ORR according to Recist 1.1 criteria with reported median DOR. In addition, the FDA provided important guidance on clinical design considerations for different lines of therapy and platinum-sensitive and resistant patient populations.

Drug	Registrational Clinical Trials	Indication	Base for approval
<b>Olaparib (Lynparza)</b> Approved December 2014	Single arm, open label, Phase 2 (Study 42)	Germline BRCA mutation ≥3 prior lines of chemotherapy	N=137 ORR: 34% - platinum-resistant: 30% mDoR: 7.9 mo
<b>Rubraca (Rucaparib)</b> Breakthrough in April 2015 Approved December 2016	Single arm, open label, Phase 2 (Study 10 and ARIEL2)	Germline and/or somatic BRCA mutation ≥2 prior lines of chemotherapy	N=106 ORR: 42% platinum-resistant: 25% mDoR: 6.7 mo-9.2 mo

Figure 3: Examples of previous US FDA accelerated approvals in ovarian cancer (source: FDA website)

In addition, IMV submitted a protocol amendment for a predictive enrichment approach to the phase 2 DeCide1 trial, and further discussed those details with the FDA during the Type B meeting. The phase 2 primary end point, based on ORR per Recist 1.1 criteria, is intended to confirm the high response rate and duration of clinical benefits observed in previously announced results in a patient population defined by a clinical biomarker based on baseline tumour burden.

The Corporation believes that there is still an urgent medical need in advanced recurrent ovarian cancer (Sources: 1. NCCN Guidelines Ovarian Cancer V2.2018; SEER Ovarian Cancer; JCO, vol 33; 32 Nov 2015, Gyn Onc 133(2014) 624-631):

- Nearly 70% of ovarian cancers are diagnosed in advanced stage;
- The overall 5-year survival rate is 46.5%, and only 29% for advanced disease;
- Most patients develop advanced, platinum-resistant, poor prognosis disease; and
- Limited options exist with current single-agents at 6-30% response rates and median progression free survival (“mPFS”) of 2.1 - 4.2 months.

The Corporation believes that it has the potential to be “best-in-class” in the competitive landscape of recurrent ovarian cancer as other immunotherapeutic treatments tested in this patient population (Incyte Corporation’s epacadostat, Merck’s Keytruda, and Pfizer/Merck KGaA’s Bavencio) are unlikely to proceed into registration trials based on the published results available:




Figure 4: Recurrent ovarian cancer immunotherapy competitive landscape

Subject to phase 2 results, IMV plans to schedule a follow-up meeting with FDA to finalize the design of a potential pivotal trial based on ORR and DOR.

The Corporation’s clinical strategy with this trial is to establish monotherapy activity in order to increase value and de-risk clinical development, and to target late stage unmet medical needs for a shorter path to clinical demonstration and first regulatory approval.

The Corporation currently anticipates that, in addition to general clinical expenses, which are distributed amongst the various clinical projects, the costs to complete this phase 2 clinical trial are estimated at \$2,500 of which \$1,000 is expected to occur in 2019.

Combinations

*Phase 2 clinical trial in DLBCL – SPiReL Phase 2 (investigator-sponsored)*

This phase 2 study is a combination trial with Merck’s KEYTRUDA® (pembrolizumab) in patients with measurable or recurrent DLBCL led by Sunnybrook Research Institute (investigator-sponsored). This investigator sponsored trial, announced initially in May 2017, is designed to evaluate the safety and efficacy of DPX-Survivac, Merck’s KEYTRUDA® (pembrolizumab), and low-dose cyclophosphamide. Primary and secondary end points include:

- Safety profile; and
- ORR and DOR using Recist 1.1 criteria.

The non-randomized, open label study is expected to enroll 25 evaluable participants in Canada. As of August 8, 2019, 12 patients have been enrolled across four different clinical sites in Canada. Following the release of positive data in June 2019, IMV agreed with the principal investigator to increase the number of sites recruiting patients from five to nine.

Researchers conducting the investigator sponsored study are testing the novel immunotherapy combination in patients whose DLBCL expresses survivin, a tumour antigen highly expressed in 60 percent of DLBCL patients. DPX Survivac stimulates the immune system to produce T cell responses targeting survivin.

On June 12, 2019, IMV provided updated data on this study. Five of the first six patients demonstrated clinical benefit, including four patients with tumour regressions and the combination continued to demonstrate an acceptable safety profile.

Updated SPiReL data highlights:

At the time of data cut-off for this analysis, 11 patients were enrolled in the trial. Efficacy data from the first six evaluable patients are based on modified Cheson criteria<sup>1</sup>:

- Two patients achieved a complete radiological response:
  - These patients have shown the best survivin specific T-cell responses to DPX-Survivac among the analyzed samples; and
  - One patient with a complete response (CR) has completed the one-year study period.
- One patient achieved a partial response (PR) at first on treatment scan;
- Two patients have reached stable disease:
  - Each of these patients has remained progression free for six and eight months while on treatment;
- Objective Response Rate (ORR): 3/6 (50%);
- Disease Control Rate (DCR): 5/6 (83%);
- One patient with bulky disease progressed at first scan;
- Two subjects are not evaluable, coming off trial at day seven and day 28;
- The treatment combination appears to be well tolerated with only two serious adverse events related to treatment (low white blood count and low neutrophil count); and
- Radiological results from three additional patients are pending.

<sup>1</sup>Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J. and Diehl, V. (2007). Revised Response Criteria for Malignant Lymphoma. *Journal of Clinical Oncology*, 25(5) DOI: 10.1200/JCO.2006.09.2403

The Corporation currently anticipates that, in addition to general clinical expenses, which are distributed amongst the various clinical projects, its share of the cost to complete this study will be approximately \$1,500, of which \$1,000 is expected to be spent in 2019.

#### *Phase 2 basket trial in 5 solid tumour indications*

On September 11, 2018, the Corporation announced the expansion of its clinical program with a phase 2 basket trial in collaboration with Merck evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide, and Merck's KEYTRUDA® (pembrolizumab), in patients with select advanced or recurrent solid tumours.

The open-label, multicenter, phase 2 basket study will evaluate the safety and efficacy of the immunotherapeutic combination in patients with bladder, liver (hepatocellular carcinoma), ovarian, or non-small cell lung NSCLC cancers, as well as tumours shown to be positive for the microsatellite instability high (MSI-H) biomarker. Investigators plan to enroll up to 184 patients across five indications in 20 medical centers in Canada and the United States.

The ASCO defines a basket clinical study as a trial that investigates the effects of a drug regimen in multiple tumour types that share a common molecular target, regardless of where the disease originated.

This is the third clinical trial evaluating the combination of DPX-Survivac, low dose cyclophosphamide, and KEYTRUDA® (pembrolizumab) in advanced recurrent cancers.

As at August 8, 2019, nine clinical sites were open and 15 patients had been enrolled across the five indications. There are also nine site initiation visits already scheduled that will bring the total of active sites to 18 in the short term. The Corporation expects to disclose preliminary data in the second half of 2019 and currently anticipates that, in addition to general clinical expenses, which are distributed amongst the various clinical projects, \$12,600 is estimated to be spent for the safety lead-in for this trial, with \$5,000 is estimated to be spent in 2019.

*Phase 2 clinical trial in ovarian cancer (investigator-sponsored)*

In February 2017, the Corporation announced an investigator-sponsored phase 2 clinical trial in ovarian cancer in combination with Merck's checkpoint inhibitor pembrolizumab in patients with recurrent, platinum-resistant ovarian cancer. University Health Network's ("UHN") Princess Margaret Cancer Centre will conduct the phase 2 non-randomized, open-label trial designed to evaluate the potential anti-tumour activity of the combination of pembrolizumab, DPX-Survivac, and low-dose cyclophosphamide. It is expected to enroll 42 subjects with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study's primary objective is to assess overall response rate. Secondary study objectives include progression free survival rate, overall survival rate, and potential side effects, over a five-year period. At this stage, the Corporation has no specific plan on the next steps after this trial as it will have to be assessed with its partner based on the clinical trial results.

As of July 29, 2019, 13 patients were enrolled in the trial and the Corporation will disclose results once provided by the UHN Princess Margaret Cancer Centre and currently anticipates that, in addition to general clinical expenses, which are distributed amongst the various clinical projects, its share of the costs to complete this study, expected to be spent in 2019, are estimated at \$400.

*DPX-SurMAGE*

In March 2019, IMV announced that CQDM, a Canadian bio-research consortium, had awarded a grant for a collaboration among IMV Inc., Centre de recherche du CHU de Quebec-Universite Laval ("CHU") and La Fondation du CHU de Quebec ("FCHUQc"). The collaboration will receive a grant of up to \$1.2 million from the CQDM and \$300 from the FCHUQc over three years, to develop a novel dual target T cell therapy for an initial clinical application in bladder cancer. IMV expects to contribute \$1.7M over the next three years towards the project.

The work will target immunogenic peptides from the MAGE protein family member A9 (MAGE-A9). This protein is frequently expressed in various human cancers including bladder, lung and kidney. These peptides will be combined with selected immunogenic peptides from the survivin protein composing the DPX-Survivac T cell drug candidate.

The researchers believe that MAGE-A9 and survivin peptides presented on the surface of cancer cells can be used to program T cells to destroy tumours and may represent ideal targets for anti-cancer T cell immunotherapies. The collaborators will combine these peptides with IMV's proprietary DPX technology to develop a first-in-class dual target T cell therapy (DPX-SurMAGE).

DPX-SurMAGE will be initially evaluated in preclinical studies. Upon successful completion of these preclinical evaluations, researchers are aiming to test the candidate in two clinical studies in patients with:

- Muscle invasive bladder cancer combined with an anti-PD-1 and intermittent low-dose cyclophosphamide (CPA) prior to cystectomy; and
- Low-grade highly recurrent non muscle invasive bladder cancer combined with CPA prior to transurethral resection.

This collaboration is expected to span a three-year period and as part of the collaboration agreement, IMV holds an exclusive option to in-license intellectual property related to this collaboration.

During the quarter, IMV met with Health Canada for a pre-clinical trial application meeting. The objectives of this meeting were to present and discuss the strategy for the development (including pre-clinical and clinical plans) of DPX-SurMAGE, to

ensure it was aligned with the agency's expectations. The agency agreed with the approach for pre-clinical, manufacturing and clinical development and made suggestions to facilitate its review by the agency.

IMV currently expects to start a phase 1 clinical trial in 2020.

#### *Orphan Drug Status and Fast Track Designation*

The Corporation announced, in November 2016, that the European Medicines Agency (EMA) had granted orphan drug designation status to IMV's DPX-Survivac in ovarian cancer. In July 2015, the FDA also granted orphan drug status to DPX-Survivac for the treatment of ovarian cancer. This designation is valid for all applications of DPX-Survivac in ovarian cancer without restriction to a specific stage of disease.

IMV had previously received FDA fast track designation for DPX-Survivac. The designation is intended for patients with no measurable disease after their initial surgery and chemotherapy.

#### ***Other Programs***

##### Oncology

###### *DPX-NEO*

On January 17, 2019, treatment of the first patient occurred in the phase 1 trial evaluating neoepitopes formulated in the Corporation's proprietary DPX delivery platform in patients with ovarian cancer. The study is part of the Corporation's DPX-NEO program, which is a continuing collaboration between Uconn Health and IMV to develop neoepitope-based anti-cancer therapies.

Investigators will assess the safety and efficacy of using patient-specific neoepitopes discovered at Uconn Health and formulated in IMV's proprietary DPX-based delivery technology in women with ovarian cancer. Investigators plan to enroll up to 15 patients in the phase 1 study. Uconn Health is financing the trial with IMV providing materials and advice.

The Corporation expects to disclose results when provided by Uconn Health.

###### *DPX-E7*

On April 17, 2017, the Corporation announced that the first study participant has been treated in a phase 1b/2 clinical study evaluating an investigational cancer target for HPV (E7) formulated in DPX and in combination with low-dose cyclophosphamide in patients with incurable oropharyngeal, cervical, and anal cancers related to HPV.

Dana-Farber is leading the DPX -E7 study through a \$1.5 million research grant from Stand Up To Cancer and the Farrah Fawcett Foundation to clinically evaluate collaborative translational research that addresses critical problems in HPV-related cancers. The Dana-Farber study is a single center, open label, non-randomized clinical trial that will investigate the safety and clinical efficacy in a total of 44 treated participants. Its primary objectives are to evaluate changes in CD8+ T cells in peripheral

blood and tumour tissue, and to evaluate the safety in HLA-A2 positive patients with incurable HPV-related head and neck, cervical, or anal cancers. IMV has the option to produce the DPX-E7 vaccine if it proves successful in the clinical trials.

The Corporation expects to disclose results when provided by Dana-Farber.

### Other Applications

#### *Product Overview*

A component of the Corporation's business strategy is partnering the DPX platform within infectious and other diseases. The DPX platform has the potential to generate a rapid and robust immune response, often in a single dose. The unique single-dose capability could prove to be beneficial in targeting difficult infectious and other disease candidates.

#### *RSV*

The Corporation has performed preclinical research activities for a vaccine targeting RSV, which is the second leading cause of respiratory illness in infants, the elderly, and the immunosuppressed. Currently, there is no vaccine available for this virus and IMV is seeking to develop a novel vaccine formulation to be used in elderly and healthy adults, including women of child-bearing age. IMV has in-licensed the RSV antigen exclusively from VIB VZW, a non-profit life sciences research institute funded by the Flemish government, to expand its pipeline of vaccine candidates. The novel RSV antigen being evaluated in DPX is based on the short hydrophobic protein present at low levels on the surface of the RSV virion. But, more importantly, it is also present on the surface of RSV-infected cells. This vaccine has a unique mechanism of action in which the resultant antibodies bind to and destroy infected cells rather than directly bind to and neutralize the free virus.

#### *Phase 1 clinical trial in RSV*

A phase 1 clinical study has been conducted in Canada with the Corporation's RSV vaccine candidate in healthy adults. The RSV vaccine is formulated in IMV's proprietary DPX platform and is initially being developed to protect the elderly population from infection. The phase 1 study, which was the first clinical trial of a DPX-based vaccine in an infectious disease indication, evaluated the safety and immune response profile of the RSV vaccine candidate in 40 healthy older adult volunteers (age 50-64 years) and two dose cohorts, with 20 subjects in each cohort.

In July 2016, the Corporation announced positive interim results from this trial. Investigators analyzed the safety and immune response data of all participants up to study day 84. The safety analysis indicates that DPX-RSV was well tolerated among all study participants, with no SAEs recorded. Furthermore, immunogenicity data supported DPX-RSV's ability to generate a relevant immune response; the vaccine candidate obtained antigen-specific antibody responses in 75 percent of subjects vaccinated with the lower dose and 100 percent of those vaccinated with the higher dose.

In October 2016, the Corporation announced positive topline results from this trial. The report outlined that more than nine months after the last vaccination, 15 of 16 participants (93%) who received DPX-RSV demonstrated antigen-specific immune responses. The vaccine candidate also continued to have a positive safety profile and was well tolerated with no SAEs among all study participants.

On April 12, 2017, the Corporation announced additional positive data from an extended evaluation of patients in this trial. An amendment had been submitted to Health Canada to test subjects who received the higher dose of vaccine out to one year after the booster vaccination. In the 25µg dose cohort, which was the only dose tested out to one year, 100 percent of older adults (7/7 immune responders) vaccinated with DPX-RSV maintained the antigen-specific immune responses one year after receiving the booster dose. At one year, the antibody levels measured were still at peak with no sign of decrease.

On September 27, 2018, IMV announced results of ongoing research to further explore the novel MOA of its vaccine candidate. New data from a preclinical study highlighted the effects of two potential approaches to preventing RSV, comparing a single dose bovine version of DPX-RSV to a two-dose conventional investigational bovine RSV vaccine. Researchers found that IMV's vaccine candidate yielded strong antigen-specific immune responses and a protective effect on disease pathology. The degree of protection was comparable between the two vaccine candidates.

In this study, researchers compared the effects of both the IMV and conventional RSV vaccine approaches among bovines with known RSV infections (the bovine animal model is considered an optimal model of RSV infection). Researchers administered



one dose of DPX-bRSV to one cohort; the second received two doses of a subunit RSV bovine vaccine. Researchers measured immune response with an antibody titer test and assessed disease pathology with a lung lesion score and other clinical parameters (such as body temperature changes).

They found SH antibodies in 14 of the 15 subjects that received DPX-bRSV, and the improvements observed in disease pathology were comparable between the two cohorts. These were the first bovine animal health data to directly correlate the vaccine-induced immune response against IMV's novel RSV target – the SH viral protein– with measures of disease protection.

Conventional RSV vaccine candidates target either the F or G proteins of the virus and provide protection by neutralizing the RSV virus. Clinical measures of efficacy focus on the amount of neutralizing antibodies in the bloodstream. DPX-RSV works differently; it targets the SH viral ectodomain of the RSV virus and, instead of neutralizing the virus, it enables the immune system to recognize and destroy infected cells. Because there are no neutralizing antibodies resulting from the DPX-RSV MOA, a different clinical assessment is required to determine the vaccine candidate's protective effect. IMV has exclusive worldwide licenses on applications that target the SH ectodomain antigen in RSV. The Corporation intends to explore opportunities to out-license this product to potential partners.

#### *Malaria*

In 2016, IMV was awarded a subcontract by Leidos, a health, national security, and infrastructure solutions company, to evaluate IMV's DPX platform for the development of peptide-based malaria vaccine targets. The subcontract is funded through Leidos' prime contract from the U.S. Agency for International Development ("USAID") to provide vaccine evaluations in the preclinical, clinical, and field stages of malaria vaccine development. Leidos and IMV are working together to identify adjuvant and antigen combinations that can be used to protect against malaria and, with the DPX delivery system, formulate promising vaccine candidates for potential clinical testing.

In November 2017, an expansion of this collaboration was announced. Following the achievement of several preclinical milestones in the collaboration with USAID, Leidos and USAID selected the DPX-based platform as one of the preferred formulations for further development under a new contract extension. Under the new subcontract, the collaborators will conduct additional research that focuses on identifying the most promising target-formulation combinations.

#### *Zoetis Collaboration*

On August 31, 2017, the Corporation announced the achievement of several milestones in its ongoing collaboration with global animal health company Zoetis to develop cattle vaccines. In recent controlled studies, the IMV formulations met efficacy and duration of immunity endpoints against two disease targets. These results will enable Zoetis to advance two IMV-formulated vaccine candidates into late-stage testing.

#### *Licensing Agreements*

While the Corporation is focused on developing a pipeline of cancer immunotherapies, it is also pursuing opportunities to license its platform technology to other parties interested in creating enhanced vaccines on an application-by-application basis.

In April 2018, IMV signed a licensing agreement and granted SpayVac-for-Wildlife (SFW Inc.) a license to two of its proprietary delivery platforms. SFW Inc. has global exclusive rights to use both of these platforms to develop humane, immune-contraceptive vaccines for control of overabundant, feral and invasive wildlife populations against royalties on sales.

## **MARKET OVERVIEW**

### *Cancer Immunotherapies*

Cancer is considered one of the most widespread and prevalent diseases globally. According to Global Cancer Facts & Figures, 4<sup>th</sup> edition (released in 2018 by the American Cancer Society), it is predicted that new cancer cases will rise to 27.5 million and the number of cancer deaths to 16.3 million by 2040 simply due to the growth of the aging population. Conventional cancer treatment involves surgery to remove the tumour whenever possible, as well as chemotherapy and radiation. Chemotherapies are widely used, despite their associated toxicities, because they interfere with the ability of cancer cells to grow and spread. However, tumours often develop resistance to chemotherapies, thus limiting their efficacy in preventing tumour recurrence.

Despite recent advances, independent sources note a high unmet medical need in cancer therapy, noting the median survival rate remains poor. Cancer immunotherapies may provide new and effective treatments. According to a Market & Markets report released in January 2017, the global immunotherapy drug market is projected to reach USD\$201.52 billion by 2021 from USD\$108.41 billion in 2016, growing at a compound annual growth rate (“CAGR”) of 13.5% during the forecast period of 2016 to 2021. The major players operating in the immunotherapy drug market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Corporation (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).

Cancer immunotherapy seeks to harness the immune system to assist in the destruction of tumours and to prevent their recurrence. There has been significant interest in the field of cancer immunotherapy stemming from recent clinical success in prolonging patient survival with novel compounds. The ability to apply these appropriately has resulted from a greater understanding of the immune dysfunction that is characteristic of cancer. One area in which there have been breakthroughs has been in the area of checkpoint inhibitors, which are compounds that target key regulatory molecules of the immune system. Yervoy® (anti CTLA 4, or ipilimumab, developed by Bristol Myers Squibb) was the first compound in this class to be approved for use in advanced metastatic melanoma. In cancer, these regulators (CTLA 4, PD 1 and its ligand PD L1) act to inhibit CD8 T cell-mediated anti-tumour immune responses that are crucial for tumour control. Monoclonal antibodies that target PD 1 and PD L1 have shown unusual efficacy in cancer patients, with a significant percentage of patients experiencing durable response to these therapies. Several of these compounds have been approved in multiple indications. Merck’s KEYTRUDA® (pembrolizumab) and Bristol Myers Squibb’s OPDIVO® (nivolumab) received FDA approval in 2014 for advanced melanoma patients who have stopped responding to other therapies. These therapies have subsequently been approved for use in other advanced cancers including bladder cancer, non-small cell lung cancer, Hodgkin’s Lymphoma, squamous cell carcinoma of the head and neck and stomach cancer. In addition, KEYTRUDA® in particular has been approved for use in cancers with a specific molecular indication irrelevant of cancer type, having been approved in May 2017 for use to treat solid tumours having a biomarker for microsatellite instability (MSI-H), which is a defect in the DNA repair pathway. This represents about 5% of a number of different tumour types, including colorectal, breast, prostate, and thyroid cancers.

These drugs have been shown to be helpful in treating several types of cancer but with success only in a limited percentage of patients. It is not yet known exactly why, though researchers have noticed that these drugs seem to work especially well for patients whose cancer cells have a higher number of mutations.

Key opinion leaders in the field have indicated that the solution lies in combining checkpoint inhibitors with other cancer treatments and that the ideal combination is likely to be a therapy that drives tumour specific immune responses. These include novel T cell-based therapies. These therapies fit well with checkpoint inhibition therapy because they simultaneously activate strong tumour-specific T cell activation, while also releasing the brakes on immune suppression. The success of such combinations should allow pharmaceutical companies to significantly expand the market of their checkpoint inhibitors.

The Corporation believes that T cell therapies will become an important component of these novel combination immunotherapies, with the potential of synergistic benefits to become an essential part of a multi-pronged approach for the treatment of cancer.

## **INTELLECTUAL PROPERTY**

The Corporation strives to protect its intellectual property in established, as well as emerging, markets around the world. The Corporation’s intellectual property portfolio relating to its platform technology includes 16 patent families, the first of which contains eight patents issued in five jurisdictions (United States, Europe, Canada, Japan, and Australia). The 15 other families collectively contain 38 patents issued in 10 jurisdictions (United States, Europe, Canada, Australia, Japan, India, Israel, Singapore, China, and, separately, Hong Kong) and 54 pending patent applications in 9 jurisdictions. Taking into account the validations of the European patents, the Corporation’s intellectual property portfolio includes 91 patents. More details on the Corporation’s intellectual property strategy and patents can be found in the AIF filed on SEDAR at [www.sedar.com](http://www.sedar.com).

The Corporation owns registered trademarks in the United States, Canada, and Europe.

## RECENT AND QUARTERLY DEVELOPMENTS

### *Key developments and achievements*

During the quarter, the Corporation amended its loan agreement in the principal amount of \$5 million with the Province of Nova Scotia to extend the maturity date of the loan, which was originally August 9, 2020. The amended loan agreement provides that the Corporation shall now start repaying the balance of the principal amount only in January 2021 by making 60 monthly principal payments of \$83 plus interest from January 2021 to December 2025. Extending the loan payments over time will allow IMV to focus its cash resources on further development of its clinical programs and research and development. The annual interest rate remains at the Province's cost of funds plus 1%.

The Corporation also announced:

- On June 12, 2019, IMV provided updated data on the phase 2 combination trial with Merck's Keytruda® (pembrolizumab) in DLBCL and at the first "on treatment" assessment, five of the first six patients demonstrated clinical benefit, including four patients with tumour regressions. Two patients reached a complete radiological response, one a partial response and two had stable disease while on study. In addition, the combination continued to demonstrate an acceptable safety profile.

Updated SPiReL data highlights:

At the time of data cut-off for this analysis, 11 patients were enrolled in the trial. Efficacy data from the first six evaluable patients are based on modified Cheson criteria<sup>1</sup>:

- Two patients achieved a complete radiological response:
  - These patients have shown the best survivin specific T-cell responses to DPX-Survivac among the analyzed samples; and
  - One patient with a complete response (CR) has completed the one-year study period;
- One patient achieved a partial response (PR) at first on treatment scan;
- Two patients have reached stable disease:
  - Each of these patients has remained progression free for six and eight months while on treatment;
  - ORR: 3/6 (50%); ◦ Disease Control Rate (DCR): 5/6 (83%);
  - One patient with bulky disease progressed at first scan;
  - Two subjects are not evaluable, coming off trial at day seven and day 28;
  - The treatment combination appears to be well tolerated with only two serious adverse events related to treatment (low white blood count and low neutrophil count); and
  - Radiological results from three additional patients are pending.
- On June 3, 2019, investigators shared new positive data for IMV's DeCide1 clinical trial at the 2019 ASCO annual meeting.

New data from evaluable patients from the phase 2 monotherapy arm of the trial indicated the potential for DPX-Survivac to impact solid tumour growth in hard-to-treat ovarian cancer patients. Longer-term follow-up from the phase 1b portion of the trial continued to demonstrate that the levels of survivin-specific T cells in the blood of patients – a measure of DPX-Survivac's novel MOA – correlated with durable clinical benefits.

In a poster presentation, Dr. Janos L. Tanyi, MD, PhD, assistant professor of obstetrics and gynecology at the Hospital of the University of Pennsylvania, provided an update on the clinical results from the first patients enrolled in the phase 2 monotherapy cohort. Researchers have enrolled 19 of 28 participants to date:

- Of seven patients evaluable at data cut-off in the monotherapy arm, five showed signs of treatment benefits, including reduction of target lesions in two patients, while two patients progressed;
- Within the group of four patients with low tumour burden – a potential predictor of response – three showed stable diseases including two reductions in tumour burden continuing the positive trend seen in earlier results;

- All subjects evaluable for T cell responses (five of five) showed survivin specific T cell activation in the blood, four of five showed a robust response. IHC analysis for tumour infiltration is continuing; and
- Treatments have been well tolerated.

The data also highlighted long-lasting responders from the phase 1b portion of the study with key takeaways as follows:

- Prolonged duration of clinical benefits reaching up to more than two years, surpassing the progression-free survival to previous treatments, including platinum-based chemotherapy;
  - Long-lasting clinical benefits and high levels of survivin specific T cells are associated with long-term treatment;
  - One subject has received DPX-Survivac for more than 21 months so far. This finding is the longest duration of treatment for DPX-Survivac on record to date; and
  - It is supportive of DPX Survivac’s ability to maintain high levels of survivin-specific T cells in the blood over a prolonged period of time.
- On April 3, 2019, that it presented preclinical research at the American Association for Cancer Research (AACR) Annual Meeting 2019 that demonstrated how the MOA of IMV’s proprietary DPX technology can enhance a broad spectrum of immune cell infiltration into tumours, which included T cells, Natural Killer (NK) cells, and macrophages. Analysis also revealed the differentiated characteristics of the immune cell responses and the potential implications for enhanced anti-tumour activity. In the poster titled, T-distributed stochastic neighbor embedding (t-SNE) analysis of tumour infiltrating lymphocytes after treatment with a T cell activating therapy identifies a unique population of recruited CD8+ T cells and novel options for combination immunotherapy, IMV researchers used specialized data analytics to examine how DPX-based agents, when combined with CPA, induced T cells to infiltrate tumours and attack cancerous cells. The study closely examined the types of immune cell responses and how and why they were able to affect disease. The data indicated that this approach stimulated the infiltration of a broad base of immune cells into tumours, including T cells, NK cells, and macrophages. The specific T cell population that moved into tumours could be grouped based on the co-expression of different checkpoint molecules such as PD-1 and Tim-3. However, those stimulated to infiltrate tumours generally did not express CTLA-4 (a protein found on T cells that inhibits the immune response).

#### SELECTED FINANCIAL INFORMATION

	Three months ended June 30, 2019 \$	Three months ended June 30, 2018 \$	Six months ended June 30, 2019 \$	Six months ended June 30, 2018 \$
Loss for the period	(5,051)	(5,196)	(10,994)	(8,263)
Basic and diluted loss per share	(0.10)	(0.12)	(0.23)	(0.19)

	As at June 30, 2019 \$	As at December 31, 2018 \$
Cash and cash equivalents	26,904	14,895
Total assets	37,345	22,925
Long term debt	7,972	8,069

**RESULTS FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2019, COMPARED TO THE THREE AND SIX-MONTHS ENDED JUNE 30, 2018**

	Q2 2019	Q2 2018	Six Months ended June 30, 2019	Six Months ended June 30, 2018
	\$	\$	\$	\$
Revenue	186	129	268	226
Research and development	3,803	2,605	7,816	4,487
General and administrative	2,184	2,640	4,144	3,930
Government assistance	(1,142)	(189)	(1,488)	(464)
Accreted interest	392	269	790	536
<b>Net loss and comprehensive loss for the period</b>	<b>5,051</b>	<b>5,196</b>	<b>10,994</b>	<b>8,263</b>

**Revenue**

Revenue increased by \$57 in Q2 2019 in comparison with Q2 2018 and by \$42 since the beginning of the year. This is mainly attributable to an interest income of \$73 since the beginning of the year as a result of the public offering completed in March.

**Research and development expenses**

R&D expenses include salaries and benefits, expenses associated with the clinical trials of DPX-Survivac, clinical research and manufacturing of DPX-Survivac and DPX-SurMAGE, consulting fees paid to various independent contractors with specific expertise required by the Corporation, the cost of animal care facilities, laboratory supplies, peptides and other raw materials, insurance, as well as other R&D related expenses.

The Corporation's R&D efforts and related expenses included costs surrounding the Corporation's clinical trials of DPX-Survivac, namely the phase 2 DeCidE1 clinical trial in ovarian cancer, phase 2 clinical trial collaboration with Merck in ovarian cancer, phase 2 clinical trial collaboration with Merck in DLBCL, phase 2 basket trial in 5 indications with Merck and costs related to the Corporation's ongoing R&D activities associated with the investigation, and analysis and evaluation of other potential product candidates and technologies.

Research and development expenses consist of the following:

	Q2 2019	Q2 2018	Six Months Ended June 30, 2019	Six Months Ended June 30, 2018
	\$	\$	\$	\$
General research and development expenses	870	526	1,408	1,013
DPX-Survivac preclinical and clinical expenses	1,864	1,227	4,218	1,881
Salaries and benefits	949	709	1,940	1,357
Non-cash stock-based compensation	84	118	185	187
Non-cash depreciation of equipment	36	25	65	49
<b>Total</b>	<b>3,803</b>	<b>2,605</b>	<b>7,816</b>	<b>4,487</b>

The increase in general R&D expenses from \$1,013 in the first half of 2018 to \$1,408 in 2019 is mainly attributable to \$247 in expenses relating to the DPX-SurMAGE collaboration with CQDM, CHU, and FCHUQc, a \$155 increase in regulatory consulting. A \$147 increase in raw materials and supplies offset by a \$85 decrease in rent expense as a result of rent now being allocated entirely to G&A.

The increase of \$2,337 in DPX-Survivac preclinical and clinical expenses compared with 2018 is mainly attributable to increased clinical activity including: expenses related to the basket trial (\$2,003) and milestone payments for the investigator-sponsored phase 2 clinical trial in ovarian cancer in combination with Merck's checkpoint inhibitor pembrolizumab (\$109).

The increase in R&D salaries in 2019 is mainly attributable to the hiring of thirteen new R&D positions (two at a director level) since the beginning of 2018.

#### General and administrative expenses

G&A expenses consist of the following:

	Q2 2019	Q2 2018	Six Months Ended June 30, 2019	Six Months Ended June 30, 2018
	\$	\$	\$	\$
General and administrative expenses, excluding salaries	1,488	1,652	2,639	2,502
Salaries and benefits	581	498	1,225	956
Non-cash stock-based and deferred share unit compensation	33	458	120	421
Non-cash depreciation of equipment	82	32	160	51
<b>Total</b>	<b>2,184</b>	<b>2,640</b>	<b>4,144</b>	<b>3,930</b>

In 2019, G&A expenses, excluding salaries, are consistent with 2018. This can be further explained by the share consolidation, NASDAQ listing, and name change expenditures incurred in Q2 2018 being offset in 2019 by increased insurance premiums and directors' fees following the NASDAQ listing in 2018.

Salaries and benefits increased by \$83 in Q2 2019 and by \$269 since the beginning of the year due to two new positions since the beginning of 2018, including a senior director of investor relations and communications and a VP of Business Development, as well as an overall increase in compensation for the senior executive team.

The decrease in non-cash stock-based and deferred share unit compensation in 2019 compared with 2018, is explained by an increase of \$202 in stock-based compensation related to new positions, offset by a decrease in the fair value of DSUs of \$503 related to fluctuation in the share price.

The increase in depreciation compared to 2018 is attributable to the leasehold improvements, equipment and leased space and associated with the new facility occupied since Q2 2018.

#### Government assistance

Government assistance consists of the following:

	Q2 Fiscal 2019	Q2 Fiscal 2018	Six Months Ended June 30, 2019	Six Months Ended June 30, 2018
	\$	\$	\$	\$
Investment tax credits ("ITC")	294	181	640	440
Government loans and assistance	848	8	848	24
<b>Total</b>	<b>1,142</b>	<b>189</b>	<b>1,488</b>	<b>464</b>

The increase in investment tax credits in 2019 is explained by the increase in R&D salaries and raw materials as well as increased clinical trial activity being performed in Canada.

The increase in government loans and assistance in 2019 is attributable to the revaluation of the low interest-bearing government loan from the Province of Nova Scotia upon receipt of the extension and amended repayment plan.

#### Accreted Interest

Accreted interest relates entirely to the valuation of low interest-bearing government loans which are repayable based on a percentage of future gross revenue and is comparable to 2018.

#### Net loss and comprehensive loss

The net loss and comprehensive loss was \$5,044 or \$0.10 per basic and diluted share for Q2 2019, \$152 lower than the net loss and comprehensive loss of \$5,196 or \$0.12 per basic and diluted share for Q2 2018. For the six months ended June 30, 2018, the net loss and comprehensive loss was \$10,987 or \$0.23 per basic and diluted share compared to \$8,263 or \$0.19 per basic and diluted share for the six months ended June 30, 2019.

#### CASH FLOWS, LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2019, the Corporation had cash and cash equivalents of \$26,904 and working capital of \$28,305, compared to \$14,895 and \$12,247, respectively as at December 31, 2018.

Since the Corporation's inception, operations have been financed through the issuance of equity securities, debt, revenue from licenses, cost recoveries from collaborations, interest income on funds available for investment, government assistance and tax credits.

During the first six months of 2019, \$14,497 was used in operating activities. This included the reported net loss of \$10,994 prior to being decreased for non-cash expenses including DSU compensation, depreciation, accretion of long-term debt and lease obligations, loss on disposal of assets and stock-based compensation. The Corporation had a net decrease of cash of \$4,059 as a result of changes in working capital balances.

Sources of cash included: \$29,456 raised through financing activities less cash issuance costs of \$2,499; and \$117 through the exercise of stock options and warrants. The Corporation used \$162 to repay long-term debt and lease obligations during the period.

During the six-month period ended June 30, 2019, the Corporation purchased furniture and equipment for ongoing research and operating activities for an aggregate amount of \$406.

The Corporation aims to maintain adequate cash and cash resources to support planned activities which include: phase 2 DeCidE1 clinical trial in ovarian cancer with DPX-Survivac; the two phase 2 investigator-sponsored combination trials with DPX-Survivac and Merck's checkpoint inhibitor, pembrolizumab in ovarian cancer and DLBCL; the basket trial in 5 indications with DPX-Survivac and Merck's checkpoint inhibitor, pembrolizumab; and other research and development activities, business development efforts, administration costs, and intellectual property maintenance and expansion.

At June 30, 2019, the Corporation had approximately \$30 million of existing and identified potential sources of cash including:

- cash and equivalents of \$26.9 million; and
- amounts receivable and investment tax credits receivable of \$3.1 million.

For the first half of 2019, the Corporation's "cash burn rate" (defined as net loss for the period adjusted for operations not involving cash – interest on lease obligation, depreciation, accretion of long-term debt, stock-based compensation and DSU compensation) was \$10.4 million. Based on the current business plan and depending on the timing of certain clinical expenses, the Corporation forecasts the cash burn rate to be between \$5 million to \$6 million per quarter for 2019, as it continues to execute its clinical plan.

It is common for early-stage biotechnology companies to require additional funding to further develop product-candidates until successful commercialization of at least one product candidate. IMV's product candidates are still in the early-development stage of the product cycle and therefore are not generating revenue to fund operations. The Corporation continuously monitors its liquidity position, the status of its development programs including those of its partners, cash forecasts for completing various stages of development, the potential to license or co-develop each vaccine candidate, and continues to actively pursue alternatives to raise capital, including the sale of its equity securities, debt and non-dilutive funding.

Management believes that its cash resources of \$26.9 million and its additional potential cash resources of \$3.1 million, as at June 30, 2019, will be sufficient to fund operations for the next twelve months while maintaining adequate working capital well into 2020. The Corporation continually reassesses the adequacy of its cash resources, evaluating existing clinical trials, research projects and/or potential collaboration opportunities, to determine when and how much additional funding is required.

#### JUNE 2017 EQUITY OFFERING AND USE OF PROCEEDS

On June 21, 2017, the Corporation completed a public offering, issuing 7,692,308 common shares pre-consolidation (2,403,846 post-consolidation) at a price of \$1.30 per share pre-consolidation (\$4.16 post-consolidation) for aggregate proceeds of \$10,000. The Corporation intends to use the net proceeds of this offering for the research and development and clinical advancement of its cancer and infectious disease vaccine candidates and for working capital and general corporate purposes. The table below provides the amount used to date and any variances (except for working capital and general corporate purposes).

<b>Intended Use of Proceeds</b>	<b>Estimated amount</b> \$	<b>Amount to date</b> \$	<b>Variances</b>
phase 2 clinical trial in DLBCL with Merck	2,400	1,541	No variances anticipated
phase 1 clinical trial for multiple indications	4,200	4,123	No variances anticipated

#### FEBRUARY 2018 EQUITY OFFERING AND USE OF PROCEEDS

On February 15, 2018, the Corporation completed a public offering, issuing 7,187,500 common shares pre-consolidation (2,246,094 post-consolidation) at a price of \$2.00 per share pre-consolidation (\$6.40 post-consolidation) for aggregate proceeds of \$14,375. The Corporation intends to use the net proceeds of this offering to continue to advance the Corporation's pipeline and conduct a phase 1 basket trial in up to five indications to be identified, for research and development, working capital, and for general corporate purposes. The table below provides the amount used to date and any variances (except for working capital and general corporate purposes).

<b>Intended Use of Proceeds</b>	<b>Estimated amount</b> \$	<b>Amount to date</b> \$	<b>Variances</b>
Clinical trials in 2019	4,800	840	No variances anticipated
Research & development in 2019	5,300	4,444	No variances anticipated



## MARCH 2019 EQUITY OFFERING AND USE OF PROCEEDS

On March 6, 2019, the Corporation completed a public offering, issuing 5,404,855 common shares pre-consolidation (including 504,855 common shares upon the exercise of the underwriters' over-allotment option on March 11, 2019) at a price of \$5.45 per share for aggregate proceeds of \$29.5M. The Corporation intends to use the net proceeds of this offering to accelerate the development of DPX-Survivac in combination with Keytruda as part of the basket trial in selected advanced or recurrent solid tumours in bladder, liver (hepatocellular carcinoma), ovarian or non-small-cell lung cancers, as well as tumours shown to be positive for the microsatellite instability high biomarker and for general corporate purposes. The table below provides the amount used to date and any variances (except for working capital and general corporate purposes).

Intended Use of Proceeds	Estimated amount \$	Amount to date \$	Variances
Phase 2 clinical trial for multiple indications	16,000	Nil	No variances anticipated

## SUMMARY OF QUARTERLY RESULTS

The selected quarterly financial information<sup>(1)</sup> for the past eight financial quarters is outlined below: (in thousands of dollars, except for amounts per share)

	Q2-2019	Q1-2019	Q4-2018	Q3-2018	Q2-2018	Q1-2018	Q4-2017	Q3-2017
<b>Total Revenue</b>	186	82	133	125	129	96	66	53
<b>Total Expenses</b>	5,237	6,025	7,818	6,112	5,325	3,163	4,997	2,175
<b>Loss</b>	(5,051)	(5,943)	(7,685)	(5,987)	(5,196)	(3,067)	(4,931)	(2,122)
<b>Basic and Diluted Loss per Share</b>	(0.10)	(0.13)	(0.17)	(0.14)	(0.12)	(0.07)	(0.13)	(0.06)

(1) Unless otherwise noted, financial information in thousands of Canadian dollars and prepared in accordance with IFRS.

Revenues from quarter to quarter may vary significantly. Revenues are non-recurring by nature and are generated by license agreements as well as contract research agreements. It is also important to note that historical patterns of expenses cannot be taken as an indication of future expenses. The amount and timing of expenses and availability of capital resources vary substantially from quarter to quarter, depending on the level of R&D activities being undertaken at any time and the availability of funding from investors or collaboration partners.

## OUTLOOK FOR THE REMAINING OF 2019

The Corporation has many clinical studies ongoing and expects the following timing to disclose results for the following studies:

Milestones	Key dates
Preliminary clinical results Basket trial in 5 indications	H2 2019
Topline monotherapy clinical results in Ovarian	H2 2019
Clinical results update in the DLBCL combination trial (investigator-sponsored)	H2 2019

The exact timing of disclosure of the above results could differ from our expectations but are currently management's best estimate.

## **RELATED PARTY TRANSACTIONS**

For the first six months of 2019, there were no related party transactions (2018 - \$nil).

## **CONTRACTUAL OBLIGATIONS**

There is no material change in the contractual obligations of the Corporation since the beginning of the 2019 fiscal year. Details on the contractual obligations of the Corporation can be found in the annual audited consolidated financial statements and related notes for the year ended December 31, 2018.

## **OFF-BALANCE SHEET ARRANGEMENTS**

The Corporation was not party to any off-balance sheet arrangements as of June 30, 2019.

## **OUTSTANDING SECURITIES**

As of August 8, 2019, the number of issued and outstanding common shares was 50,612,125 and a total of 1,997,232 stock options, warrants, and deferred share units were outstanding.

## **RISKS AND UNCERTAINTIES**

The Corporation is a clinical-stage company that operates in an industry that is dependent on a number of factors that include the capacity to raise additional capital on reasonable terms, obtain positive results of clinical trials - including clinical trials on DPX-Survivac, obtain positive results of clinical trials without serious adverse or inappropriate side effects, and obtain market acceptance of its product by physicians, patients, healthcare payers and others in the medical community for commercial success, etc. An investment in the Corporation's common shares is subject to a number of risks and uncertainties. An investor should carefully consider the risks described in the Corporation's AIF and the registration statement on Form 40-F filed with the U.S. Securities and Exchange Commission, as well as the other information filed with the securities regulators before investing in the Corporation's common shares. If any of the such described risks occur, or if others occur, the Corporation's business, operating results and financial condition could be seriously harmed and investors may lose a significant proportion of their investment.

There are important risks which management believes could impact the Corporation's business. For information on risks and uncertainties, please also refer to the "Risk Factors" section of our most recent AIF filed on SEDAR at [www.sedar.com](http://www.sedar.com) and included in the registration statement on Form 40-F filed on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

## **DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROLS OVER FINANCIAL REPORTING**

### Disclosure Controls and Procedures

The Chief Executive Officer (the "CEO") and the Chief Financial Officer (the "CFO") of the Corporation are responsible for establishing and maintaining the Corporation's disclosure controls and procedures ("DCP") including adherence to the Disclosure Policy adopted by the Corporation. The Disclosure Policy requires all staff to keep senior management fully apprised of all material information affecting the Corporation so that they may evaluate and discuss this information and determine the appropriateness and timing for public disclosure.

The Corporation maintains DCP designed to ensure that information required to be disclosed in reports filed under applicable securities laws, is recorded, processed, summarized and reported within the appropriate time periods and that such information is accumulated and communicated to the Corporation's management, including the CEO and CFO, to allow for timely decisions regarding required disclosure.

The CEO and CFO have evaluated whether there were changes to the DCP during the six-month period ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, the DCP. No such changes were identified through their evaluation.

In designing and evaluating DCP, the Corporation recognizes that any disclosure controls and procedures, no matter how well conceived or operated, can only provide reasonable, not absolute, assurance that the objectives of the control system are met, and management is required to exercise its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

#### Internal Control over Financial Reporting

The Corporation's management, including the CEO and the CFO, are responsible for establishing and maintaining adequate internal control over financial reporting ("ICFR") for the Corporation to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. The fundamental issue is ensuring all transactions are properly authorized and identified and entered into a well-designed, robust and clearly understood accounting system on a timely basis to minimize risk of inaccuracy, failure to fairly reflect transactions, failure to fairly record transactions necessary to present financial statements in accordance with IFRS, unauthorized receipts and expenditures, or the inability to provide assurance that unauthorized acquisitions or dispositions of assets can be detected.

The CEO and CFO have evaluated whether there were changes to the ICFR during the six-month period ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, the ICFR. No such changes were identified through their evaluation.

The Corporation's ICFR may not prevent or detect all misstatements because of inherent limitations. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions or deterioration in the degree of compliance with the Corporation's policies and procedures.

#### **BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES**

The consolidated financial statements have been prepared in accordance with the IFRS as issued by the IASB. The accounting policies, methods of computation and presentation applied in the consolidated financial statements are consistent with those of previous financial year except for business development and investor relations expenses are now presented in general and administrative expenses on the consolidated statements of loss and comprehensive loss. Certain comparative figures have been reclassified to conform the presentation adopted in the current year for general and administrative expenses.

The significant accounting policies of IMV are detailed in the notes to the annual audited consolidated financial statements for the year ended December 31, 2018 filed on SEDAR [www.sedar.com](http://www.sedar.com) and included in the registration statement on Form 40-F filed on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

#### **CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS**

Estimates and assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The determination of estimates requires the exercise of judgement based on various assumptions and other factors such as historical experience and current and expected economic conditions. Actual results could differ from those estimates.

Critical judgements in applying the Corporation's accounting policies are detailed in the annual audited consolidated financial statements for the year ended December 31, 2018 filed on SEDAR [www.sedar.com](http://www.sedar.com) and included in the registration statement on Form 40-F filed on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

#### **FINANCIAL INSTRUMENTS**

Financial instruments are defined as a contractual right or obligation to receive or deliver cash on another financial asset. The Corporation recognizes financial instruments based on their classification. Depending on the financial instrument's classification, changes in subsequent measurements are recognized in net loss or other comprehensive loss.

A description of the financial instruments, their fair value and risk management is included in the Corporation's annual audited consolidated financial statements for the year ended December 31, 2018 filed on SEDAR [www.sedar.com](http://www.sedar.com) and included in the registration statement on Form 40-F filed on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).

*(Signed) Frédéric Ors*  
Frédéric Ors  
Chief Executive Officer

*(Signed) Pierre Labbé*  
Pierre Labbé  
Chief Financial Officer

**August 8, 2019**

**FORM 52-109F2**  
**CERTIFICATION OF INTERIM FILINGS**  
**FULL CERTIFICATE**

I, Frederic Ors, Chief Executive Officer of IMV Inc., certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended June 30, 2019.
  2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
  3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
  4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in *National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.
  5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:
    - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that:
      - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
      - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
    - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
  - 5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal Control – *Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission.
-

5.2 **ICFR - material weakness relating to design:** N/A

5.3 **Limitation on scope of design:** N/A

6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on April 1, 2019 and ended on June 30, 2019 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: August 8, 2019

(signed) Frederic Ors

Frederic Ors  
Chief Executive Officer

---

**FORM 52-109F2**  
**CERTIFICATION OF INTERIM FILINGS**  
**FULL CERTIFICATE**

I, Pierre Labbé, Chief Financial Officer of IMV Inc., certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended June 30, 2019.
  2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
  3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
  4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in *National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.
  5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:
    - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that:
      - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
      - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
    - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
  - 5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal Control – *Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission.
-

5.2 **ICFR - material weakness relating to design:** N/A

5.3 **Limitation on scope of design:** N/A

6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on April 1, 2019 and ended on June 30, 2019 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: August 8, 2019

(signed) Pierre Labbé

Pierre Labbé

Chief Financial Officer

---